Ono 3307 Free Base | CAS# 76472-28-1 (free base) | synthetic protease inhibitor

MedKoo Cat#: 414580 | Name: Ono 3307 Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ono 3307 Free Base is a new synthetic protease inhibitor

Chemical Structure

Ono 3307 Free Base

CAS#76472-28-1 (free base)

Theoretical Analysis

MedKoo Cat#: 414580

Name: Ono 3307 Free Base

CAS#: 76472-28-1 (free base)

Chemical Formula: C14H14N4O4S

Exact Mass: 334.0736

Molecular Weight: 334.35

Elemental Analysis: C, 50.29; H, 4.22; N, 16.76; O, 19.14; S, 9.59

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

76472-29-2 (mesylate); 76472-28-1 (free base)

Synonym

Ono 3307 Free Base; Ono3307; Ono-3307

IUPAC/Chemical Name

Benzoic acid, 4-((aminoiminomethyl)amino)-, 4-(aminosulfonyl)phenyl ester

InChi Key

YFUQTMNUQVFBBS-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H14N4O4S/c15-14(16)18-10-3-1-9(2-4-10)13(19)22-11-5-7-12(8-6-11)23(17,20)21/h1-8H,(H4,15,16,18)(H2,17,20,21)

SMILES Code

O=C(OC1=CC=C(S(=O)(N)=O)C=C1)C2=CC=C(NC(N)=N)C=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 334.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Matsuoka S, Futagami M, Ohno H, Imaki K, Okegawa T, Kawasaki A. Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo. Jpn J Pharmacol. 1989 Dec;51(4):455-63. doi: 10.1254/jjp.51.455. PMID: 2515329. 2: Hirano T, Manabe T, Tobe T. Impaired hepatic energy metabolism in rat acute pancreatitis: protective effects of prostaglandin E2 and synthetic protease inhibitor ONO 3307. J Surg Res. 1992 Sep;53(3):238-44. doi: 10.1016/0022-4804(92)90041-w. PMID: 1528049. 3: Hirano T, Manabe T, Calne R, Tobe T. Effects of acute pancreatitis on hepatic secretion of lysosomal enzymes into bile and hepatic lysosomal fragility: protective effects of a new synthetic protease inhibitor, ONO 3307. Scand J Gastroenterol. 1992;27(3):227-32. doi: 10.3109/00365529208999954. PMID: 1502486. 4: Yoshikawa T, Takeda S, Naito Y, Kondo M. Protective effects of ONO-3307, a new synthetic protease inhibitor against experimental disseminated intravascular coagulation in rats. Thromb Res. 1990 Oct 1;60(1):1-7. doi: 10.1016/0049-3848(90)90334-9. PMID: 2278034. 5: Hirano T, Manabe T, Ohshio G, Nio Y. Protective effects of combined therapy with a protease inhibitor, ONO 3307, and a xanthine oxidase inhibitor, allopurinol on temporary ischaemic model of pancreatitis in rats. Nihon Geka Hokan. 1992 May 1;61(3):224-33. PMID: 1444702. 6: Sobajima H, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Sakai Y, Ishiguro H, Tanikawa M, Nakae Y. Effect of a new synthetic trypsin inhibitor on taurocholate-induced acute pancreatitis in rats. Pancreas. 1993 Mar;8(2):240-7. doi: 10.1097/00006676-199303000-00016. PMID: 8460097. 7: Hirano T, Manabe T, Tobe T. Protection by a new synthetic protease inhibitor, ONO3307, of the rat exocrine pancreas during acute edematous pancreatitis induced by a supramaximal dose of caerulein in comparison with FOY007. Pharmacology. 1992;45(2):107-16. doi: 10.1159/000138986. PMID: 1381836. 8: Hirano T, Yotsumoto TM, Ando K, Tobe T. [Changes of acinar cells in the pancreato-biliary duct ligation with exocrine pancreatic stimulation model in rats; protective effects of a new potent protease inhibitor, ONO3307]. Nihon Geka Hokan. 1991 Sep 1;60(5):342-53. Japanese. PMID: 1726453. 9: Hirano T, Manabe T, Tobe T. Cytoprotective effects of prostaglandins and a new potent protease inhibitor in acute pancreatitis. Am J Med Sci. 1992 Sep;304(3):154-63. doi: 10.1097/00000441-199209000-00003. PMID: 1282294. 10: Ono S, Tamakuma S, Mochizuki H, Kinoshita M, Ohkusa Y, Aosasa S, Oda Y, Ohe H. Clinical and experimental studies on the role of platelet-activating factor (PAF) in the pathogenesis of septic DIC. Surg Today. 1993;23(3):228-33. doi: 10.1007/BF00309232. PMID: 8467174.